Subject Index

ABC, *See* Association of Biotechnology Companies
Absorbents for color removal, 188
ABSP, *See* Agricultural Biotechnology for Sustainable Productivity
Abstract journals, 129
Abstracts, 165–166
Africa, biotechnology development in, 204–213
Agency for International Development (USAID), 109
Agricultural biotechnology, World Bank support for, 74–75
Agricultural Biotechnology for Sustainable Productivity (ABSP), 102–110
Agricultural competitiveness, 114–116
Agricultural productivity in fragile lands, 116
Agricultural research, 85–86
Agriculture and biotechnology in developing countries, 80–92
Agriculture
  complexity of, 53
  model systems in, 55–57
  novel methods in, 54
  problem transfer, 54
Agrobiotechnology in developing world, 111–126
AMINOMAT, 40–41
Antidisease vaccines in malaria, 8
Antigenic diversity in malaria, 8
Antigens as targets of immunity in malaria, 11
Apomixis, 63–67
Appropriate technology, issue of, 90
Asexual blood stage vaccines in malaria, 11–13
Association of Biotechnology Companies, 109
  research team, 105–106

Baculovirus vector, 28
Barriers to technology transfer, 233–235
Biesenthal Vaccine Initiative (BVI), 47, 49–52
Bio/Afrique, 204–213
BIOCAT, 176
Biochemical model of agricultural production, 82
Biodiversity, 67, 117
Bioindicators, 61
Bioinformatics, 135–144, 145–152, 159–164
BioLink, 109
Biological data, management of, 153–158
Biological databank development, 155–158
Biological weapons, 43–47
Biological Weapons Convention, 43–47
Bioremediation, 181
Biosafety, 108
Biosafety regulation, 124, 220
  advocacy groups, 223–225
  application sector, 223–225
  company size, 223–225
  human, material, and budgetary resources, 223
  public acceptance, 223–225
  regulatory policies and politics, 221–223
  risk assessment, 220–221
  socioeconomic impact, 223–225
  timing and direction of innovation, 223–225
Biotechnology, 165–172, 232–255
  and agriculture in developing countries, 80–92
  cooperation, 43–44
  development strategy in developing countries, 122
  for developing countries, 194–202
  industry, 112–114
  information, 135–144
  networks, 135–144
  obstacles to commercialization, 214–231
  R&D in developing countries, 153–158
  research, public and private partnership, 93–99
  supply and demand issues, 89–90
  support policies in Latin America, 121–122
  transfer, plant, 93–99
  transfer to developing countries, 22–30
BIOTRACK, 175–176
Bose Institute, 240, 246–248
Brain drain, 195
BVI, *See* Biesenthal Vaccine Initiative

CAB International in information dissemination, 165–172
CAL, *See* Computer-assisted learning
CAMBIA, *See* Center for the Application of Molecular Biology to International Agriculture
Cameroun, 204
Capability-building by developing countries, 236–237
Capitalization, 210
Caribbean, research and development in, 117–122
CD-ROM, 166–167
Cell and Molecular Biology Research Center, 198–200

Subject Index

ABC, *See* Association of Biotechnology Companies
Absorbents for color removal, 188
ABSP, *See* Agricultural Biotechnology for Sustainable Productivity
Abstract journals, 129
Abstracts, 165–166
Africa, biotechnology development in, 204–213
Agency for International Development (USAID), 109
Agricultural biotechnology, World Bank support for, 74–75
Agricultural Biotechnology for Sustainable Productivity (ABSP), 102–110
Agricultural competitiveness, 114–116
Agricultural productivity in fragile lands, 116
Agricultural research, 85–86
Agriculture and biotechnology in developing countries, 80–92
Agriculture
  complexity of, 53
  model systems in, 55–57
  novel methods in, 54
  problem transfer, 54
Agrobiotechnology in developing world, 111–126
AMINOMAT, 40–41
Antidisease vaccines in malaria, 8
Antigenic diversity in malaria, 8
Antigens as targets of immunity in malaria, 11
Apomixis, 63–67
Appropriate technology, issue of, 90
Asexual blood stage vaccines in malaria, 11–13
Association of Biotechnology Companies, 109
  research team, 105–106

Baculovirus vector, 28
Barriers to technology transfer, 233–235
Biesenthal Vaccine Initiative (BVI), 47, 49–52
Bio/Afrique, 204–213
BIOCAT, 176
Biochemical model of agricultural production, 82
Biodiversity, 67, 117
Bioindicators, 61
Bioinformatics, 135–144, 145–152, 159–164
BioLink, 109
Biological data, management of, 153–158
Biological databank development, 155–158
Biological weapons, 43–47
Biological Weapons Convention, 43–47
Bioremediation, 181
Biosafety, 108
Biosafety regulation, 124, 220
  advocacy groups, 223–225
  application sector, 223–225
  company size, 223–225
  human, material, and budgetary resources, 223
  public acceptance, 223–225
  regulatory policies and politics, 221–223
  risk assessment, 220–221
  socioeconomic impact, 223–225
  timing and direction of innovation, 223–225
Biotechnology, 165–172, 232–255
  and agriculture in developing countries, 80–92
  cooperation, 43–44
  development strategy in developing countries, 122
  for developing countries, 194–202
  industry, 112–114
  information, 135–144
  networks, 135–144
  obstacles to commercialization, 214–231
  R&D in developing countries, 153–158
  research, public and private partnership, 93–99
  supply and demand issues, 89–90
  support policies in Latin America, 121–122
  transfer, plant, 93–99
  transfer to developing countries, 22–30
BIOTRACK, 175–176
Bose Institute, 240, 246–248
Brain drain, 195
BVI, *See* Biesenthal Vaccine Initiative

CAB International in information dissemination, 165–172
CAL, *See* Computer-assisted learning
CAMBIA, *See* Center for the Application of Molecular Biology to International Agriculture
Cameroun, 204
Capability-building by developing countries, 236–237
Capitalization, 210
Caribbean, research and development in, 117–122
CD-ROM, 166–167
Cell and Molecular Biology Research Center, 198–200

Center for the Application of Molecular Biology to International Agriculture, 68
Central Research Institute for Food Crops, 107
Children's Vaccine Initiative, 1–6
Chimeric genes, 28
China, 167
Chiron Corp., 204
CIBCM, *See* Cell and Molecular Biology Research Center
Circumsporozoite protein (CSP) in malaria vaccine, 9–10
Cloning, 199
Color elimination from drinking water, 188
Combinatorial libraries, 39–40
Commercial biotechnology development in Africa, 204–213
Commercialization
  of MEOR, 187–188
  obstacles to, 214–231
Competition in Latin America, 114
Competitiveness, 226–228
Computer literacy, 138–139
Computer-assisted learning (CAL)
  authorware, 180
  copyright transportability, 179
  courseware, 178–179
  guide, 180
  video disk, 179
Computer user education, 141
Computer user interactive processes, 157
Concept development, 233
CONICIT, 196–197
Conservation, 197–198
Contaminants, 200
Core Database in Biotechnology, 147
CRIFC, *See* Central Research Institute for Food Crops
Crop protection, 169–171
Current Contents, 145
Cycles of selection, 38
Cytotoxic immunity in rotavirus infection, 33

Data acquisition, 157
Data elements, identification of, 156–157
Databanks, 202
Databases, 136–138, 153, 165–166, 175–176
Developmental procedures, identification of, 156
Diagnostic kits, rapid, 22–30
Diagnostics, 170
DNA plant technology, 107
Drinking water regulations, 188–192
Drugs, new, 36–41
Dual-threat agents, 43–45
Dualla, Cameroun, 212

Economic factors in oil production, 185
Electronic compendium, 169–171
Electronic information, 130–131
Electronic mail, 196
Engineered plants, 66
Environmental degradation, 201
Environmental dependence, 55
Environmental pollution, 181
Environmental reporters, 61
Epidermal growth factor, 211
Evaluation procedures, 158
Evolution *in vitro*, 37–38
Expression vector, cold-adapted, 34

Farmer control of engineered plants, 66
Field trials, organization and design of, 185–186
Forestry, 169

Gene structure, 58
Genetic engineering, 181
Global competitiveness, 214
GUS system, 59

Hazardous compounds, 181
Hemagglutinin and fusion proteins, 25–28
Hepatitis B, 211
Home pregnancy tests, 206
Human chorionic gonadotropin (hCG), 209
Human genetics, 198
Human immunodeficiency virus, 27–28
Human resource development, 108
Humoral immunity in rotavirus infection, 33
Hybridoma, 208

IAEA, *See* International Atomic Energy Agency
IBI, *See* Initiative for Biotechnology Implementation
ICGEB, *See* International Centre for Genetic Engineering and Biotechnology
ICI Seeds Americas, 107
IDB, *See* InterAmerican Development Bank
ILDIS, *See* International Legume Database and Information Service
Immunity, acquisition of, in malaria, 8
Immunization in malaria, 8
Immunoassay, 209
In vivo reporters, 59
INBio, 197
India, plant biotechnology project in, 239–253
Industry without research, 235

Information Resource for the Release of Organisms into the Environment, 173–176
Information, 145–152
  access, 140
    in developing countries, 78
  costs, 140–141
  explosion, 136–138
  literacy, 138–139
  policies, 144
  production, 139
  representation, 140
  retrieval systems, 141
  scientific, growth of, 128–134
  technology, 165–172
  users, 138–139
  variety, 139
Initiative for Biotechnology Implementation (IBI), 204
Institutional innovation, 91
Intellectual property issues, 125
Intellectual property management, 77
Intellectual property rights, 108, 225–226
InterAmerican Development Bank, 200
Interfaces, 142
Interferon, 28
Interleukin-2, 211
International agricultural research centers, 123–124
International Atomic Energy Agency (IAEA), 200
International Centre for Genetic Engineering and Biotechnology (ICGEB), 44
International Finance Corp. (IFC), 206, 212–213
International Legume Database and Information Service (ILDIS), 159–164
Internet, 137–138
Investment in developing countries, 123
IRRO, *See* Information Resource for Release of Organisms into the Environment
  Secretariat, 174
ISAAA, 93–101

Jennerian approach to rotavirus vaccination, 33–34

Knowledge base, 233

LAC system, 59
Latin America
  biotechnology in, 194–202
  research and development in, 117–122
Less developed countries, 228–229
Libraries and information centers, 143
Libraries for research, 129–130
Libraries on beads, 38

Macromicro linkages, 88
Maize technology, 82
Malaria, 7–14, 206
  infection transmitted by, 8
  merozoites in, 8
  ookinetes in, 8
  schizont in, 8
  sporozoites in, 8, 9
  vaccines, 7–14
Male sterility created using molecular technologies, 65
Marketing, 87
Medical defense of military, 46
MEDLINE, 153
MEOR history, 184
Merozoites in malaria, 8
Microbial enhancement of oil recovery, 183–188
Microbial Network in Europe (MINE), 148
Microbial opportunities in oil production, 184
Microbial Strain Data Network (MSDN), 148, 173
Mimics of epitopes (MIMOTOPE), 39
MINE, *See* Microbial Network in Europe
Model systems, 53–73
Molecular biology, 196
Molecular biology technology in developing countries, 22–30
Molecular Genetic Resource Service, 69–70
Molecular technology, apomixis created through, 65
Monoclonal antibodies, 206–207
MSDN, *See* Microbial Strain Data Network
Multimedia CAL (computer-assisted learning), 177–180

National strategies in biotechnology, 75
New England Biolabs, 204
Nitrocellulose, 209
Nitrogen fixation efficiency, 62
Nondestructive reporter genes, 57–61
North-South information inequities, 143
Nucleotide sequence libraries, 147–148

OECD, *See* Organization for Economic Cooperation and Development
Oil production, economic factors in, 185
Oil reserves, 183

Ookinetes in malaria, 8
Organization for Economic Cooperation and Development (OECD), 82–84, 113–114
Orphan commodities, 76
Orphan crops, 69
  transformation of, 61

Parasitic diseases, vaccines against, 7–14
Patents, 200–201
Peptide design, 40–41
Peste-des-petits-ruminants virus, 25
Phage libraries, 36
Physiological reporters, 61
Pilot plants, 189–192
Plant biotechnology applications, transfer of, 93–99
Plant biotechnology project in India, 239–253
Plant virology, 198
Plasmodium falciparum, 7–8
Policy coherence, issue of, 91
Policy options in biotechnology in developing countries, 78
Pollution, environmental, 181
Polymerase chain reaction (PCR), 198
Poor science, 147
Privatization of seeds production and marketing, 86–87
Proliferation verification, 44–45

Quality control, 208

Random screening, 36
Recombinant vaccines for diseases in developing world, 22–30
Regulatory issues in releasing novel products, 77–78
Reovirus, 32–33
Reporter genes, 57–61
Research libraries in the North, 129–130
Residual oil, 183
Rinderpest, 25–28
Rockefeller Foundation, 132
Rotavirus vaccination, 32–35
Rotaviruses
  epidemiology, 32
  pathophysiology, 32
  virology, 32–33

Schizont in malaria, 8
Scientific, technological, and engineering bottlenecks, 215–216
Secreted reporter enzymes, 61
Seeds production, 86
Sentinel plants, 61–63
Simian immunodeficiency virus, 27–28
Smallpox, 23–24
Socioeconomic impact of new technologies, 75
Species diversity knowledge systems, 159–164
Sporozoite surface protein-2 (SSP2) in malaria vaccine, 10
Sporozoites in malaria, 8, 9
Structural adjustment programs in developing countries, 81
Subunit vaccine antigen, 7–8
Sustainable agricultural production processes, 116
Sustainable agriculture, 54–55
Systematic Evolution of Ligands by Exponential enrichment (SELEX), 37–38

T cell in immune response in malaria, 10
Taxonomic databases, 160–161
Technological change in agriculture, 81
Technologies, new, 74–75
Technology
  assessment, 76–77
  diffusion, 87
  integration with management, 187
  push, market pull, 182
  transfer, 87–88, 182–193, 232–233, 249–250
  transfer programs, 125
  transfer to developing countries, 22–30
Third World, transferring technology to, 192
Threshold factors
  market creation, 219–220
  market demand, 219–220
  production scale-up, 218–219
  R&D costs, 217–218
Tools
  adaptation of, 69
  development, mechanisms for, 67–68
Toxin weapons, 43–47
Trade liberalization in agriculture, 80
Transmission-blocking vaccines in malaria, 13–14
Tree biodiversity, 67

UNDP, *See* United Nations Development Program
UNEP, *See* United Nations Environmental Programme
United Nations Development Program (UNDP), 232–233
  project in India, 239–253
United Nations Environmental Programme (UNEP), 173

Vaccination, rotavirus, 32–35
Vaccines, 46–47
  anti-malarial, 7–14
  current limitations of, 1–2
  potential for development of, 2–3
  transmission-blocking, in malaria, 13–14
Vaccines for Peace (VFP), 46–47
Vaccinia virus, 23–28
Vectors, 24
  viral, 45
Venture capital, 200
VFP, *See* Vaccines for Peace

Wastes, 201
Wellcome Trust, 179
WHO, *See* World Health Organization
World Bank policies and programs in biotechnology, 74–79
World Health Organization (WHO), 204

Index of Contributors

Altman, D. W., 93–101

Bedford, B., 102–110
Bialy, H., 204–213
Bisby, F. A., 159–164
Brenner, C., 80–92

Cassani, G., 36–42
Chakrabarty, A. M., 181
Chambers, J., 102–110
Cohen, J., 102–110

Dodds, J., 102–110

Falaschi, A., ix–x
Franklin, J., 145–152

Geissler, E., 43–52
Greenberg, H. B., 32–35

Hoider, A. A., 7–21
Howe, G., 177–180

Jaffé, W. R., 111–127
James, C., 93–101
Jefferson, R. A., 53–73

Kesselman, M., 135–144
Kirsop, B. H., 173–176

Léon, P. E., 194–203
Leopold, M., 214–231

Moses, V., 182–193

Persley, G. J., 74–79

Réchaussat, L. J., 153–158

Russell, P. K., 1–6

Saracevic, T., 135–144
Scott, P. R., 165–172
Sondahl, M., 102–110
Sticklen, M., 102–110

Trigo, E. J., 111–127
Tzotzos, G. T., ix–x

Warren, K. S., 128–134
Wilson, M., 102–110

Yilma, T., 22–31

Zilinskas, R. A., 232–255